Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

Similar documents
Impact of Obesity Interventions on Managed Care

Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice

GIST (Gastrointestinal Stromal Tumor)

Product Theaters. Light refreshments provided by the American Diabetes Association will be served to the first 300 attendees.

Conference Report. Chronic Obstructive Pulmonary Disease From a Payer and Provider Lens. Managed Care & Healthcare Communications, LLC

New Prognostic Markers in Acute Myeloid Leukemia (AML)

Target Audience. approach this patient case scenario, including identifying an

Managed care faced an interesting dilemma in 2012 when the American Diabetes. Evidence-Based Diabetes Management:

Critical Pathways in Breast Cancer Treatment

Introducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals

CLINICAL GUIDELINES RESEARCH & LEADERSHIP IN THIS ISSUE. Chapter 1. Clinical Guideline for Adults With Diabetes, SP209.

Hepatitis C RESOURCE GUIDE

ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)

STEP THERAPY CRITERIA

Asia Pacific Medical Publications: NAVIGATING OUR FUTURE

Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration

DBA Design Effectiveness Awards SoloSTAR. A disposable pen injector for insulin

OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP

Applying Data to Practice: Where Do Modern Insulins Fit in My Diabetes Practice CME

Diabetes is a chronic disease associated with a variety

New Cardiovascular Horizons. Tucson. Multidisciplinary Strategies for Optimal Cardiovascular Care. Arizona February 7, 2015

Managing diabetes. Editors. Jiten Vora Royal Liverpool University Hospital Liverpool, UK. Marc Evans University Hospital of Llandough Cardiff, UK

University Alcohol Policy

The opinions expressed are the speaker s and not his company s.

June 4, Via Electronic Transmission

This time of intense change in. More than 29 million people in. Evidence-Based Diabetes Management

Avenue Therapeutics, Inc. August 2016

Assessment of performance is a focus of many

Case 2:14-cv Document 1 Filed 12/17/14 Page 1 of 12 UNITED STATES DISTRICT COURT FOR THE EASTEN DISTRICT OF LOUISIANA

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)

Improving Type 2 Diabetes Patient Health Outcomes with Individualized Continuing Medical Education for Primary Care

Use of Power Morcellators: Minimizing Liability, Assuring Safety? By Barbara Youngberg

Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML

Investor presentation. Bioshares Biotech Summit July 2017

Become A Supporting Organization

OAMT ONCOLOGY ACCOUNT MANAGEMENT TRAINING. September 20 22, 2016 ARIA Resort & Casino, Las Vegas, NV. For the Life Sciences Industry

Policy of Conflict of Interest in Clinical Research

February 13-15, 2009 Ft. Lauderdale, FL

Adverse Reactions to HIV Vaccines: Medical, Ethical, and Legal Issues. September OTA-BP-H-163 GPO stock #

Podcast/MP3 Instructions 1. Download the Podcast or MP3 audio file to your player. 2. Listen to the presentation. 3. To receive continuing education

Biochemical Society Centenary: the Last 25 Years

Decision Making Across the Lifespan

Eli Lilly and Company Tailored Therapeutics and Diagnostics

Faculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI

CORPORATE POLICY MANUAL. 1. SCOPE 1.1 Authority This policy is issued under the authority of the Senior Executive Team.

NHS BEXLEY CLINICAL COMMISSIONING GROUP GOVERNING BODY FORMAL MEETING 25 th October 2012

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

THC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases

Avenue Therapeutics, Inc. September 2016

All-Cause Costs Increase Exponentially with Increased Chronic Kidney Disease Stage

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes

Avenue Therapeutics, Inc. May 2017

Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery

How can a STRONG recommendation be based on VERY LOW quality evidence?

ALCOHOL BEVERAGE PERMIT APPLICATION INSTRUCTIONS

NDA NDA APPROVAL

REGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017

Effect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic

PARKING FOR. INSTITUTIONS AND SPECIAL EVENTS. EdWard M. Whitlock, P.E. " " ,, 1 1., 1 ' ' 1

Disclosures. Learning Objectives 4/26/2017

Evolution of the individualized treatment landscape for advanced NSCLC

www. isotopeworld.com Advanced Medical Isotope Corporation

Follicular Lymphoma RESOURCE GUIDE

Podcast/MP3 Instructions 1. Download the Podcast or MP3 audio file to your player. 2. Listen to the presentation. 3. To receive continuing education

What drives the cost of medications for diabetes? Depending on whom you ask,

Fidelity and Outcomes in Community Care

A Clinical Context Report

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

INVESTOR PRESENTATION

ALCOHOL POLICY GUIDELINES

Healthcare Professional Information & Patient Information Leaflet (PL)

CONFERENCE REPORT THE AMERICAN JOURNAL OF MANAGED CARE. Exclusive Coverage of the 2016 AMERICAN COLLEGE OF RHEUMATOLOGY ANNUAL MEETING

AGENDA MONDAY SEPTEMBER 26

Diabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust

Guidance on Generating the Three Base Fair Balance Levels (HCP advertising)

CONFERENCE REPORT THE AMERICAN JOURNAL OF MANAGED CARE. Exclusive Coverage of the NEUROSCIENCE EDUCATION INSTITUTE (NEI) 2017 CONGRESS

THE COST OF DOING NOTHING

Challenges in Diabetes Management: Glycemic Control, Medication Adherence, and Healthcare Costs

Patient 1: 31-Year-Old Female. Fingolimod treatment

Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Advanced or Metastatic Non-Small Cell Lung Cancer

Ethical Practice Guidelines on Financial Incentives from Hearing Instrument Manufacturers

NORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director

ISSUE BRIEF Conference on Clinical Cancer Research November 2014

DRUG AND ALCOHOL POLICY

The Boston Globe. March 8, 2010 Monday

Learn how you can support

CONSULTANT PHYSICIAN v SANOFI

Immuno-Oncology RESOURCE GUIDE

HILLENBRAND INDUSTRIES INC

Research and Forecast on China Insulin Market, (Sample)

Evidence based advertising. in 2018

novo nordisk R&D AT A GLANCE

Walgreens. Specialty Pharmacy Marketing Video

Clinical Review Report (Sample)

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

WALGREEN CO. FORM 8-K (Unscheduled Material Events) Filed 6/5/2006 For Period Ending 6/5/2006

Transcription:

Publishing Staff Senior Vice President of Clinical Affairs Jeff D. Prescott, PharmD, RPh Senior Clinical Projects Manager Ida Delmendo Clinical Projects Manager Tara Petersen Project Christina Doong Quality Assurance Editor David Allikas Associate Editor Jeanne Linke Design Charles Lebeda Associate Publisher Andrew Colon of Sales Sara Stewart National Account Managers Gabrielle Consola Michael Costella Corporate Chairman and CEO Mike Hennessy Vice Chairman Jack Lepping President Tighe Blazier Chief Financial Officer Neil Glasser, CPA/CFE President, Managed Markets Brian Haug Executive Vice President and General Manager John Maglione Vice President of Human Resources Rich Weisman Vice President, Executive Creative Jeff Brown Vice President of Education David Heckard December 2014 Vol. 20, No. 13, Sup. Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials Table of Contents Participating Faculty Report n Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials Robert A. Bailey, MD; Ujjwala Vijapurkar, PhD; Gary E. Meininger, MD; Marcia F.T. Rupnow, PhD; and Lawrence Blonde, MD S294 S296 Copyright 2014 by Managed Care & Healthcare Communications, LLC A Supplement to The American Journal of Managed Care www.ajmc.com PROJ A533 VOL. 20, NO. 13 n THE AMERICAN JOURNAL OF MANAGED CARE n S293

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials This supplement was supported by Janssen Pharmaceuticals, Inc. This analysis was funded by Janssen Scientific Affairs, LLC. Editorial support was provided by Bilge Yoruk, PhD, of Excerpta Medica, and was funded by Janssen Scientific Affairs, LLC. Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements. n THE AMERICAN JOURNAL OF MANAGED CARE n

n PARTICIPATING FACULTY n Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials This supplement to The American Journal of Managed Care describes the results of a post hoc analysis designed to evaluate attainment of diabetes-related quality measures with canagliflozin 100 mg, canagliflozin 300 mg, and sitagliptin 100 mg in patients with type 2 diabetes mellitus. This information may be relevant to stakeholders increasingly focused on quality measures and population health management, such as payers, healthcare delivery organizations, and clinicians. n Faculty Robert A. Bailey, MD Health Economics and Outcomes Research Janssen Scientific Affairs, LLC Lawrence Blonde, MD Ochsner Diabetes Clinical Research Unit Department of Endocrinology, Diabetes, and Metabolic Diseases Ochsner Medical Center New Orleans, Louisiana Gary E. Meininger, MD Vice President, Franchise Medical Leader Marcia F.T. Rupnow, PhD Senior Health Economics and Outcomes Research Janssen Scientific Affairs, LLC Ujjwala Vijapurkar, PhD Associate n Faculty Disclosures These faculty report relationships with the following organizations: Robert A. Bailey, MD Janssen Scientific Affairs, LLC (a company) Lawrence Blonde, MD Grants: Eli Lilly and Company, Novo Nordisk, and sanofi-aventis Honoraria: AstraZeneca, Janssen Pharmaceuticals, Inc, Merck & Co, Inc, Novo Nordisk, Quest Diagnostics, and sanofi-aventis S294 n www.ajmc.com n DECEMBER 2014

n PARTICIPATING FACULTY n Gary E. Meininger, MD Marcia F. T. Rupnow, PhD Janssen Scientific Affairs, LLC (a company) Ujjwala Vijapurkar, PhD Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey. VOL. 20, NO. 13 n THE AMERICAN JOURNAL OF MANAGED CARE n S295

n Supplement Policy Statement n Standards for Supplements to The American Journal of Managed Care All supplements to The American Journal of Managed Care are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All Journal supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to The American Journal of Managed Care will: I. Be reviewed by at least one independent expert from a recognized academic medical institution. II. Disclose the source of funding in at least one prominent place. III. Disclose any existence of financial interests of supplement contributors to the funding organization. IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication. V. Be up-to-date, reflecting the current (as of date of publication) standard of care. VI. Be visually distinct from The American Journal of Managed Care. VII. Publish information that is substantially different in form and content from that of the accompanying edition of The American Journal of Managed Care. VIII. Prohibit excessive remuneration for contributors and reviewers. IX. Carry no advertising. Publisher s Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of The American Journal of Managed Care. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.